Last reviewed · How we verify
COBALAMIN
At a glance
| Generic name | COBALAMIN |
|---|---|
| Drug class | Vitamin C [EPC] |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Cobalamin deficiency
- Pernicious anemia
- Prevention of Vitamin B12 Deficiency
- Toxic effect of cyanide
Common side effects
- allergic and idiosyncratic reactions
- glucose abnormalities
- visual problems
- gastrointestinal complaints
- skin ailments
Key clinical trials
- Iron and Immune Response to Vaccine (IRONMUM) (NA)
- Clinical and Laboratory Study of Methylmalonic Acidemia
- Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older
- Effect of Vitamin D and Folic Acid on Mild Cognitive Impairment (NA)
- Frequency of Fibromyalgia Syndrome in Elderly Patients Aged 80 and Above and Its Relationship With Geriatric Parameters
- Vegan Diet and Immune-Inflammatory Outcomes in Asthma and Healthy Adults (NA)
- Microbiome and Health Indicators in People With Obesity, Prediabetes and Type 2 Diabetes Undergoing a Lifestyle Intervention (NA)
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COBALAMIN CI brief — competitive landscape report
- COBALAMIN updates RSS · CI watch RSS